Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmAsia News Australia/New Zealand Roundup: Medicines Australia, PHARMAC, Helicon, Pharmaxis

This article was originally published in PharmAsia News

Executive Summary

Medicines Australia Critical Of Labor Government's First Budget
Advertisement

Related Content

Australian Labor Government Slashes Drug Prices For Big Pharma, Delivers Tax Credits To Struggling Biotechs In 2009 Budget
Australian Labor Government Slashes Drug Prices For Big Pharma, Delivers Tax Credits To Struggling Biotechs In 2009 Budget
Australian Labor Government Slashes Drug Prices For Big Pharma, Delivers Tax Credits To Struggling Biotech In 2009 Budget
Australia’s Parliament Shoots Down Pharma Cost Recovery Bill; Lilly Closes In On Diabetes Reimbursement In NZ: Australia/New Zealand Regulatory Roundup
New Zealand’s PHARMAC Declines Funding For Roche’s Herceptin 12-Month Treatment For Early HER2 Positive Patients
Australia, New Zealand Roundup: Pharmaxis, CSL, PHARMAC
AusBiotech Chief Executive Anna Lavelle On Biotech’s Role In Asia Pacific: An Interview with PharmAsia News (Part 1 of 2)
Aussie Pharma Pharmaxis Submits Bronchitol Application to China’s State FDA
Asia More “Enlightened” Regulatory Environment – Pharmaxis CEO
Asia More “Enlightened” Regulatory Environment – Pharmaxis CEO
Advertisement
UsernamePublicRestriction

Register

SC068493

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel